How you access Endpoints News is changing
Starting today, Endpoints News will be changing how you access our journalism and how our paywall operates.
For subscribers on an Insider or Enterprise plan, nothing will change. The support we’ve received from our paying subscribers over the years has powered Endpoints’ daily coverage of the most important news in biotech and pharma. And we thank each and every one of you.
For basic subscribers, we’re moving to a metered paywall. Previously, we selected which stories would be behind the paywall and which would be free. Going forward, non-paying readers will get several free articles a month, after which we’ll ask you to become a premium subscriber to access our breaking news, our in-depth coverage of science and innovation and our richly reported features. You’ll still receive our newsletters, but accessing story content and special reports will require a paid subscription.
Many of our readers work in, invest in and regulate the biopharma industry. Endpoints is here to get you the information you need to keep up-to-the-minute on what’s happening. In return, we’re asking for your support so that we can do our part to bring you stories like our scoops on a Lyme vaccine trial gone wrong, John Carroll’s in-depth survey of top biopharma decision-makers, our report on changes in the M&A market, and coverage of the latest Alzheimer’s readouts and FDA approvals.
For those of you who already have an Insider or Enterprise subscription, there’s nothing you need to do. For non-paying readers, after you run out of free articles in a given month, you’ll be directed to our subscriptions page and can sign up (or you can do so here).
In the months to come, we’ll be enhancing our website, we’ll deliver more breaking news straight to your inbox, and we’ll continue to invest in our journalism to get you the coverage you need, when you need it.
Thank you for your support, and thanks for reading,